Page 87 - 北京京煤集团总医院第十届·2022学术年会论文集

北京京煤集团总医院 第十届·2022 学术年会论文集

Cardiology[J]. Eur J Heart Fail,2018,20(5):853-72.

[4]程明心,王军奎.钠-葡萄糖协同转运蛋白 2 抑制剂治疗 2 型糖尿病合并心力衰竭研究进展

[J].国际老年医学杂志,2022,43(1):120-2.
[5]VERMA S,MCMURRAY J J V. SGLT2 inhibitors and mechanisms of cardiovascular benefit:a

state-of-the-art review[J]. Diabetologia,2018,61(10):2108-17.
[6]MCDONAGH T A,METRA M,ADAMO M,et al. 2021 ESC Guidelines for the diagnosis and

treatment of acute and chronic heart failure [J]. Eur Heart J,2021,42(36):3599-726.

[7]2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure[J]. J Card

Fail,2022,28(5):e1-e167.

[8]ZINMAN B,WANNER C,LACHIN J M,et al. Empagliflozin,Cardiovascular Outcomes,and

Mortality in Type 2 Diabetes [J]. N Engl J Med,2015,373(22):2117-28.

[9]RAJAGOPALAN S,BROOK R. Canagliflozin and Cardiovascular and Renal Events in Type 2

Diabetes[J]. N Engl J Med,2017,377(21):2098-9.

[10]WIVIOTT S D,RAZ I,BONACA M P,et al. Dapagliflozin and Cardiovascular Outcomes in

Type 2 Diabetes[J]. N Engl J Med,2019,380(4):347-57.

[11]KOSIBOROD M,CAVENDER M A, FU A Z, et al. Lower Risk of Heart Failure and Death in
Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering

Drugs:The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New
Users of Sodium-Glucose Cotransporter-2 Inhibitors)[J]. Circulation,2017,136(3):249-59.

[12]MCMURRAY J J V,SOLOMON S D,INZUCCHI S E,et al. Dapagliflozin in Patients with

Heart Failure and Reduced Ejection Fraction [J]. N Engl J Med,2019,381(21):1995-2008.

[13]NASSIF M E,WINDSOR S L,TANG F,et al. Dapagliflozin Effects on

Biomarkers,Symptoms,and Functional Status in Patients With Heart Failure With Reduced Ejection

Fraction:The DEFINE-HF Trial [J]. Circulation,2019,140(18):1463-76.

[14]崔敏,赵倩,陈还珍.SGLT-2 抑制剂对 2 型糖尿病患者心功能及左室质量影响的 Meta 分析

[J].中国循证心血管医学杂志,2022,14(2):143-6.

[15]武锋超,蓝庆肃,马兰虎,等.SGLT2 抑制剂治疗 2 型糖尿病合并心力衰竭的疗效和安全性

的 Meta 分析[J].中国循证心血管医学杂志,2022,14(3):263-8,277.

（发表于《中国循证心血管医学杂志》2022 年 14 卷 6 期 708 页）

- 82 -